{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-22-000158","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.812403+00:00","generated_at":"2026-06-22T01:07:39.632420+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sesen Bio obtains final court approval for derivative lawsuit settlement","bullets":["U.S. District Court for Massachusetts granted final approval on Nov 8, 2022 for settlement of consolidated derivative lawsuits.","Settlement covers In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, and Tang v. Sesen Bio, Inc., Case No. 2281-cv-00135.","Company also disclosed securities class action settlement hearing set for Jan 23, 2023 in Southern District of New York.","Previously, court granted preliminary approval on Sep 2, 2022; terms in Aug 30, 2022 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-22-000158","json":"https://secwatch.observer/filing/0001485003-22-000158.json","markdown":"https://secwatch.observer/filing/0001485003-22-000158.md","text":"https://secwatch.observer/filing/0001485003-22-000158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/0001485003-22-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/sesn-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:07:39.632420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}